Cargando…

New drugs: big changes in conservative heart failure therapy?

During the last 20 years, the prognosis for heart failure (HF) with reduced ejection fraction has steadily improved due to advances in drug treatment and the consistent implementation of guideline-recommended evidence-based drug therapy. Nevertheless, the morbidity and mortality rates of patients wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Berliner, Dominik, Bauersachs, Johann
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6526100/
https://www.ncbi.nlm.nih.gov/pubmed/31106335
http://dx.doi.org/10.1093/ejcts/ezy421
_version_ 1783419826160533504
author Berliner, Dominik
Bauersachs, Johann
author_facet Berliner, Dominik
Bauersachs, Johann
author_sort Berliner, Dominik
collection PubMed
description During the last 20 years, the prognosis for heart failure (HF) with reduced ejection fraction has steadily improved due to advances in drug treatment and the consistent implementation of guideline-recommended evidence-based drug therapy. Nevertheless, the morbidity and mortality rates of patients with HF can still be improved. The prevalence of HF is high and continues to increase steadily. Thus, timely and efficient drug treatment plays a central role in improving the quality of life and prognosis for patients with HF. Current therapeutic concepts combine inhibition of the renin–angiotensin–aldosterone system with blockage of the sympathetic system. New therapeutic approaches such as selective heart rate reduction, attenuation of the degradation of natriuretic peptides by neutral endopeptidase inhibition and treatment of comorbidities (e.g. iron deficiency, diabetes mellitus, hyperkalaemia) have led to a further improvement in the survival, time-out-of hospital and quality of life of affected patients. The goal of this article was to give an overview of the current standard drug therapy for HF and the value of new therapeutic approaches implemented in recent years.
format Online
Article
Text
id pubmed-6526100
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-65261002019-05-24 New drugs: big changes in conservative heart failure therapy? Berliner, Dominik Bauersachs, Johann Eur J Cardiothorac Surg Reviews During the last 20 years, the prognosis for heart failure (HF) with reduced ejection fraction has steadily improved due to advances in drug treatment and the consistent implementation of guideline-recommended evidence-based drug therapy. Nevertheless, the morbidity and mortality rates of patients with HF can still be improved. The prevalence of HF is high and continues to increase steadily. Thus, timely and efficient drug treatment plays a central role in improving the quality of life and prognosis for patients with HF. Current therapeutic concepts combine inhibition of the renin–angiotensin–aldosterone system with blockage of the sympathetic system. New therapeutic approaches such as selective heart rate reduction, attenuation of the degradation of natriuretic peptides by neutral endopeptidase inhibition and treatment of comorbidities (e.g. iron deficiency, diabetes mellitus, hyperkalaemia) have led to a further improvement in the survival, time-out-of hospital and quality of life of affected patients. The goal of this article was to give an overview of the current standard drug therapy for HF and the value of new therapeutic approaches implemented in recent years. Oxford University Press 2019-06 2019-05-20 /pmc/articles/PMC6526100/ /pubmed/31106335 http://dx.doi.org/10.1093/ejcts/ezy421 Text en © The Author(s) 2019. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Reviews
Berliner, Dominik
Bauersachs, Johann
New drugs: big changes in conservative heart failure therapy?
title New drugs: big changes in conservative heart failure therapy?
title_full New drugs: big changes in conservative heart failure therapy?
title_fullStr New drugs: big changes in conservative heart failure therapy?
title_full_unstemmed New drugs: big changes in conservative heart failure therapy?
title_short New drugs: big changes in conservative heart failure therapy?
title_sort new drugs: big changes in conservative heart failure therapy?
topic Reviews
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6526100/
https://www.ncbi.nlm.nih.gov/pubmed/31106335
http://dx.doi.org/10.1093/ejcts/ezy421
work_keys_str_mv AT berlinerdominik newdrugsbigchangesinconservativeheartfailuretherapy
AT bauersachsjohann newdrugsbigchangesinconservativeheartfailuretherapy